With about 2.7 million episodes of rotavirus occurring each year among children under age five in the U.S., this ACIP decision highlights the importance of rotavirus disease prevention and adds this needed vaccine to the current pediatric immunization schedule. Merck is proud that its 15 years of research and development resulted in the availability of this vaccine. For the past several years we have been producing ROTATEQ and plan to meet the anticipated demand for the vaccine following this recommendation from the ACIP. Mark Feinberg